Ozanimod Medicine 09 January 2018 Extended indication RMS. Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Ozanimod Domain Neurological disorders Reason of inclusion Main indication Multiple sclerosis Extended indication RMS. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Celgene Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Capsule Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Toedieningsvorm: naast een Capsule-vorm komt Ozanimod ook als vloeistof beschikbaar voor kinderen (bron EMA). Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date September 2018 Expected Registration July 2019 Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration 0,5-1 mg References Additional remarks Expected patient volume per year Patient volume 400 - 800 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Verwachting minder patiënten dan Ocrevus. Expected cost per patient per year Cost References Prescribing Outlook 2017 Additional remarks Prescribing Outlook 2017: 'High cost drug.' Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks